Jeffrey Nelson Biography and Net Worth

Chief Operating Officer of Milestone Pharmaceuticals

Mr. Nelson serves as Milestone’s Chief Operating Officer. He has over 15 years of experience in the pharmaceutical and biotech field, working primarily in project management, clinical operations, regulatory affairs, and public finance. He brings a significant amount and variety of cross-functional experience working at small companies in late-stage drug development. Prior to Milestone Pharmaceuticals, Mr. Nelson was Vice President Program Management at Mateon Therapeutics, an orphan oncology-focused biotech company. Previously, he was the head of Clinical Operations at Axsome Therapeutics and was a key member of Chelsea Therapeutics Operations and Regulatory teams. Prior to Chelsea Therapeutics, Mr. Nelson was a sell-side equity analyst at Ladenburg Thalmann covering biotech and CRO companies for four years, and he started his career in operations and business development for the generic pharmaceutical company Cobalt Pharmaceuticals. Mr. Nelson holds a BA in Economics from Brandeis University in 2003.

What is Jeffrey Edward Nelson's net worth?: The estimated net worth of Jeffrey Edward Nelson is at least $62.56 thousand as of January 26th, 2026. Mr. Nelson owns 49,848 shares of Milestone Pharmaceuticals stock worth more than $62,559 as of August 10th. This net worth evaluation does not reflect any other investments that Mr. Nelson may own. Learn More about Jeffrey Edward Nelson's net worth.
How do I contact Jeffrey Edward Nelson?: The corporate mailing address for Mr. Nelson and other Milestone Pharmaceuticals executives is 1111 DR. FREDERIK-PHILIPS BLVD SUITE 420, MONTREAL A8, H4M 2X6. Milestone Pharmaceuticals can also be reached via phone at (514) 336-0444 and via email at [email protected]. Learn More on Jeffrey Edward Nelson's contact information.
Has Jeffrey Edward Nelson been buying or selling shares of Milestone Pharmaceuticals?: Jeffrey Edward Nelson has not been actively trading shares of Milestone Pharmaceuticals during the past quarter. Most recently, Jeffrey Edward Nelson sold 12,245 shares of the business's stock in a transaction on Monday, January 26th. The shares were sold at an average price of $1.93, for a transaction totalling $23,632.85. Following the completion of the sale, the chief operating officer now directly owns 49,848 shares of the company's stock, valued at $96,206.64. Learn More on Jeffrey Edward Nelson's trading history.
Who are Milestone Pharmaceuticals' active insiders?: Milestone Pharmaceuticals' insider roster includes David Bharucha (Chief Medical Officer), and Jeffrey Nelson (Chief Operating Officer). Learn More on Milestone Pharmaceuticals' active insiders.
Are insiders buying or selling shares of Milestone Pharmaceuticals?: During the last twelve months, insiders at the sold shares 11 times. They sold a total of 452,827 shares worth more than $1,017,948.37. The most recent insider tranaction occured on April, 16th when CEO Joseph Oliveto sold 36,500 shares worth more than $82,490.00. Insiders at Milestone Pharmaceuticals own 5.0% of the company. Learn More about insider trades at Milestone Pharmaceuticals.
Information on this page was last updated on 4/16/2026.

Jeffrey Edward Nelson Insider Trading History at Milestone Pharmaceuticals

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
1/26/2026	Sell	12,245	$1.93	$23,632.85	49,848
12/15/2025	Sell	58,007	$2.32	$134,576.24	41,993

Jeffrey Edward Nelson Buying and Selling Activity at Milestone Pharmaceuticals

Milestone Pharmaceuticals Company Overview

Milestone Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of cardiovascular medicines. The company's lead product candidate is etripamil, a novel and potent calcium channel blocker, which is in Phase III clinical trial for the treatment of paroxysmal supraventricular tachycardia in the United States and Canada; and Phase II clinical trial for the treatment of atrial fibrillation and rapid ventricular rate. It has a license and collaboration agreement with Ji Xing Pharmaceuticals to develop and commercialize etripamil prophylactic and therapeutic uses in humans, as well as with the Montreal Heart Institute, the WCN network, and other research centers. The company was incorporated in 2003 and is headquartered in Montréal, Canada.

Today's Range

Now: $1.27

$1.20

$1.28

50 Day Range

MA: $1.24

$1.04

$1.36

2 Week Range

Now: $1.27

$1.00

$3.06

Volume

1,342,655 shs

Average Volume

1,872,258 shs

Market Capitalization

$157.49 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.98